Twist Bioscience (TWST)
NASDAQ:TWST
Want to see TWST full AI Analyst Report?
TWST Stock Chart & Stats
$59.81
-$0.78(-1.71%)
At close: 4:00 PM EST
$59.81
-$0.78(-1.71%)
Day’s Range― - ―
52-Week Range$23.30 - $80.50
Previous CloseN/A
Volume152.02K
Average Volume (3M)1.70M
Market Cap
$4.74B
Enterprise Value$4.14B
Total Cash (Recent Filing)$171.67M
Total Debt (Recent Filing)$95.84M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Jul 31, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding62,271,313
10 Day Avg. Volume1,802,281
30 Day Avg. Volume1,696,256
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.56
Price to Sales (P/S)4.47
P/FCF Ratio-22.25
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue10.10
Enterprise Value/Gross Profit19.40
Enterprise Value/Ebitda-73.43
Forecast
1Y Price Target
$72.50Price Target Upside21.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.05
Revenue Forecast (FY)$446.65M
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthThirteen consecutive quarters of sequential revenue growth show durable commercial momentum and expanding adoption across therapeutics, NGS and DNA synthesis. Sustained top-line scaling improves operating leverage potential and underpins management's path to adjusted‑EBITDA breakeven over the next 2–4 quarters.
Gross Margin ExpansionMaintaining >50% gross margins reflects improving product mix, manufacturing leverage and pricing power in high-value DNA and NGS products. A sustained mid-50% gross margin level materially aids the path to adjusted EBITDA breakeven by increasing incremental profit per new dollar of revenue.
Therapeutics & Strategic PartnershipsRapid therapeutics growth and new commercial partnerships expand higher‑value, recurring revenue opportunities and move the company into integrated discovery workflows. Strong uptake by large pharma and AWS collaboration deepen market access and create durable upsell and cross‑sell pathways.
Bears Say
Negative Operating & Free Cash FlowPersistent negative operating and free cash flow reduces financial flexibility and increases reliance on external financing to fund growth and capex. Even with improving trends, multi-quarter cash burn necessitates prudent cash management and may constrain strategic investments absent further cash inflows.
Ongoing Adjusted EBITDA Losses & Rising OpExContinued adjusted EBITDA deficits and rising operating costs from commercial and infrastructure investments delay sustainable profitability. If expense growth outpaces revenue or margin improvement, the timeline to breakeven could extend and pressure returns on invested capital.
End‑Market Headwinds & Sequence Acceptance RiskWeakness in academic/government demand and remaining sequence acceptance failures pose persistent revenue and retention risks. Structural shrinkage or customer routing of orders due to acceptance gaps can cap addressable market growth and reduce lifetime customer value absent full operational remediation.
Twist Bioscience News
TWST FAQ
What was Twist Bioscience’s price range in the past 12 months?
Twist Bioscience lowest stock price was $23.30 and its highest was $80.50 in the past 12 months.
What is Twist Bioscience’s market cap?
Twist Bioscience’s market cap is $4.74B.
When is Twist Bioscience’s upcoming earnings report date?
Twist Bioscience’s upcoming earnings report date is Jul 31, 2026 which is in 45 days.
How were Twist Bioscience’s earnings last quarter?
Twist Bioscience released its earnings results on May 04, 2026. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.477 by -$0.233.
Is Twist Bioscience overvalued?
According to Wall Street analysts Twist Bioscience’s price is currently Undervalued.
Does Twist Bioscience pay dividends?
Twist Bioscience does not currently pay dividends.
What is Twist Bioscience’s EPS estimate?
Twist Bioscience’s EPS estimate is -0.48.
How many shares outstanding does Twist Bioscience have?
Twist Bioscience has 62,271,313 shares outstanding.
What happened to Twist Bioscience’s price movement after its last earnings report?
Twist Bioscience reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.477. Following the earnings report the stock price went down -6.97%.
Which hedge fund is a major shareholder of Twist Bioscience?
Currently, no hedge funds are holding shares in TWST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Twist Bioscience Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$72.50 (21.22% Upside)
$72.50 (21.22% Upside)
Blogger Sentiment
Bullish
TWST Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
News Sentiment
Bullish
Bullish news 79%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
126.49%
12-Months-Change
Fundamentals
Return on Equity
-17.46%
Trailing 12-Months
Asset Growth
13.53%
Trailing 12-Months
Company Description
Twist Bioscience
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
TWST Company Deck
TWST Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and commercial story: strong top-line growth (19% YoY), robust outperformance in therapeutics (55% YoY), gross margin above 50%, strategic partnerships (AWS) and an explicit path to adjusted EBITDA breakeven in Q4 FY2026. Offsetting these positives are ongoing adjusted EBITDA losses, higher operating expenses tied to strategic investments, a reduction in cash balances, a pending litigation settlement and certain end-market pressures (academic funding headwinds and some segment declines). Management provided clear remediation steps (cost reductions, targeted automation, acceptance-rate improvements) and raised full-year guidance, indicating confidence in execution.View all TWST earnings summariesTWST Stock 12 Month Forecast
Average Price Target
$72.50
▲(21.22% Upside)
Technical Analysis
Ownership Overview
2.97% Insiders
23.26% Mutual Funds
43.14% Other Institutional Investors
2.38% Public Companies and
Individual Investors